Researchers from Binzhou Medical University and affiliated organizations have detailed the synthesis and optimization of a new series of 1,4,5,6-tetrahydrobenzo [2,3]oxepino[4,5-d]pyrimidin-2-amine derivatives, which resulted in the identification of compound [I] as the lead candidate with potent anti-neuroinflammatory activity in vitro.

The FDA has cleared an IND application for ADEL-Y01, being jointly developed by Oscotec Inc. and Adel Inc., for the treatment of Alzheimer’s disease. A phase Ia/b study will include healthy volunteers, and participants with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease.

Phoenix Pharmalabs Inc. has reported findings from in vivo studies that demonstrated that the company’s lead compound, PPL-138, reduced symptoms of post-traumatic stress disorder (PTSD) and decreased alcohol consumption in a rat model of PTSD/alcohol use disorder (AUD). The studies were conducted at the University of Oklahoma Health Sciences Center and Florida Atlantic University under a grant from the U.S. Department of Defense.

An international team of researchers have developed a new blood test that could detect Parkinson’s disease earlier than current methods. The test, a real-time PCR-based assay, called Mito Dnadx, uses blood to identify damage to mitochondrial DNA (mtDNA) caused by the neurodegenerative condition. Based on the findings published in the journal Science Translational Medicine, the test could allow rapid, noninvasive and accurate identification of Parkinson’s disease (PD) before it causes much damage to the nervous system.

Dewpoint Therapeutics Inc. and Chemify Ltd. have partnered to develop a suite of digitally discovered and automatically synthesized novel molecules on Chemify’s programmable chemistry platform against condensate targets of interest in Dewpoint’s oncology and neurodegeneration pipeline.

“From one to many” is how Actio Biosciences Inc. describes its approach to drug development. The firm emerged with a $55 million series A financing and an eye for biological targets found in both rare and common diseases, starting with TRPV4, a target associated with Charcot-Marie-Tooth disease type 2C and other bone diseases.